文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

惊恐障碍伴或不伴广场恐惧症的药物治疗:随机对照试验的系统综述与网络Meta分析

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2022-01-19

该系统综述与网络Meta分析纳入87项随机对照试验共12800名成人惊恐障碍患者,比较12类药物的疗效与安全性。结果显示三环类抗抑郁药、苯二氮䓬类、单胺氧化酶抑制剂、SSRIs和SNRIs的缓解率均显著高于安慰剂,但前三类药物不良事件风险也显著增加。SSRIs兼具较高缓解率和较低不良事件风险,其中舍曲林和艾司西酞普兰表现最佳。

要点

  • 三环类、苯二氮䓬类、MAOIs、SSRIs、SNRIs缓解率均显著高于安慰剂。
  • 三环类、苯二氮䓬类和SSRIs不良事件风险显著高于安慰剂。
  • SSRIs兼具高缓解率和低不良事件风险,舍曲林和艾司西酞普兰表现最佳。

核心结论

  • SSRIs治疗惊恐障碍缓解率高且不良事件风险低,其中舍曲林和艾司西酞普兰与高缓解率和低不良事件风险相关。
  • 上述发现基于中等至极低 certainty 的证据,主要源于研究内偏倚、不一致性和不精确性。

研究设计与样本

  • 系统综述与网络Meta分析,检索Embase、Medline和ClinicalTrials.gov自建库至2021年6月17日。
  • 纳入87项随机对照试验,共12800名年龄≥18岁确诊惊恐障碍的成人,比较12类药物。
  • 采用随机效应模型进行直接Meta分析,并采用两阶段网络Meta分析结合累积排序曲线下面积(SUCRA)估计比较疗效。
  • 采用修订版Cochrane随机试验偏倚风险评估工具评估偏倚风险,几乎所有研究(86/87)存在一些担忧或高偏倚风险。

主要发现

  • 与安慰剂相比,三环类抗抑郁药缓解率风险比RR 1.39(95%CI 1.26至1.54),苯二氮䓬类RR 1.47(1.36至1.60),单胺氧化酶抑制剂RR 1.30(1.00至1.69),SSRIs RR 1.38(1.26至1.50),SNRIs RR 1.27(1.12至1.45)。
  • SUCRA排序显示苯二氮䓬类(84.5%,平均排名2.4)、三环类抗抑郁药(68.7%,3.8)和SSRIs(66.4%,4.0)为缓解率最高的前三类治疗。
  • 与安慰剂相比,三环类抗抑郁药不良事件风险RR 1.79(95%CI 1.47至2.19),苯二氮䓬类RR 1.76(1.50至2.06),SSRIs RR 1.19(1.01至1.41)。
  • 同时考虑缓解率和不良事件的SUCRA聚类排序图显示,SSRIs与高缓解率和低不良事件风险相关;在单个SSRIs中,舍曲林和艾司西酞普兰提供高缓解率且不良事件风险可接受。
  • 不良事件的一致性假设成立,但去除女性参与者比例高的研究和广场恐惧症研究后仍可能存在不一致性。

局限性

  • 几乎所有研究(86/87)存在一些担忧或高偏倚风险。
  • 证据确定性为中等至极低,主要源于研究内偏倚、不一致性和不精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify drug classes and individual selective serotonin reuptake inhibitors (SSRIs) with high rates of remission and low risk of adverse events in the treatment of panic disorder with or without agoraphobia. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Embase, Medline, and ClinicalTrials.gov from inception to 17 June 2021. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised controlled trials that included adults aged ≥18 years with a diagnosis of panic disorder, compared drugs used to treat the panic disorder, and measured the outcomes of interest, including remissions, dropouts, and adverse events. METHODS: Risk of bias in the included studies was assessed using the revised Cochrane risk of bias tool for randomised trials. Direct meta-analyses were performed using random effects models. A two stage network meta-analysis with surface under the cumulative ranking curve (SUCRA) was used to estimate the comparative efficacy of drug classes and individual SSRIs. RESULTS: 87 studies including a total of 12 800 participants and 12 drug classes were eligible for inclusion. Almost all the studies (86/87) had some concern or were at high risk of bias. Network meta-analysis of remission with consistent results indicated that tricyclic antidepressants, benzodiazepines, monoamine oxidase inhibitors, SSRIs, and serotonin-noradrenaline reuptake inhibitors (SNRIs) were associated with significantly higher remission rates than placebo, with risk ratios of 1.39 (95% confidence interval 1.26 to 1.54), 1.47 (1.36 to 1.60), 1.30 (1.00 to 1.69), 1.38 (1.26 to 1.50), and 1.27 (1.12 to 1.45), respectively. SUCRAs identified benzodiazepines (84.5%, mean rank=2.4), tricyclic antidepressants (68.7%, 3.8), and SSRIs (66.4%, 4.0) as the top three best treatments for remission. However, tricyclic antidepressants, benzodiazepines, and SSRIs were also significantly associated with increased risk of adverse events compared with placebo, with risk ratios of 1.79 (1.47 to 2.19), 1.76 (1.50 to 2.06), and 1.19 (1.01 to 1.41), respectively. Consistency assumption of adverse events was upheld but could still be present on removal of studies with high percentages of women participants and those with agoraphobia. A SUCRA cluster ranking plot considering both remission and adverse events among all drug classes indicated that SSRIs were associated with high remission and low risk of adverse events. Among individual SSRIs, sertraline and escitalopram provided high remission with an acceptable risk of adverse events. CONCLUSION: The findings suggest that SSRIs provide high rates of remission with low risk of adverse events for the treatment of panic disorder. Among SSRIs, sertraline and escitalopram were associated with high remission and low risk of adverse events. The findings were, however, based on studies of moderate to very low certainty levels of evidence, mostly as a result of within study bias, inconsistency, and imprecision of the findings reported. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020180638.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022. PMID: 35045991. doi:10.1136/bmj-2021-066084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。